"Biotech's Radio Reboot: Molecular Partners Tunes Cancer Code at JP Morgan, Aktis IPO Debugs VC Drought"

Molecular Partners AG (MOLN) presented at the 44th Annual J.P. Morgan Healthcare Conference, held on January 15, 2026, at 1:30 PM EST, with Co-Founder and CEO Patrick Amstutz, Co-Founder and Executive VP of Projects Michael Stumpp, and Senior Vice President of Research & Technology Daniel Steiner in attendance. The presentation was part of the last day of the conference, which was hosted by JPMorgan Chase & Co, and featured a Q&A session after the presentation, allowing attendees to engage with the Molecular Partners team. According to Patrick Amstutz, the conference marked a positive start to 2026, with increased confidence in a biotech turnaround after a few challenging years, and the team received positive feedback on the field of radiotherapy, particularly following the successful IPO of Aktis Oncology, a radiotherapy company. The presentation focused on radiotherapy and the company's outlook for 2026, with Amstutz expressing gratitude to the conference hosts and highlighting the reenergized interest in radiotherapy, as evident from the IPO of Aktis Oncology, led by Matt and his team. With over 157,000 followers tuning in, the event provided a significant platform for Molecular Partners to showcase its progress and future plans, and as Amstutz noted, "I think we can look forward to 2026" with increased confidence in the biotech sector.